RJMty19

RJMty19 is a first-in-class, humanized anti-CD19 chimeric antigen receptor (CAR)-engineered allogeneic double-negative T cell (DNT) therapy. It is designed as an off-the-shelf cellular immunotherapy for the treatment of B-cell malignancies and certain autoimmune diseases. The product consists of DNTs derived from healthy donors, which are depleted of CD4+ and CD8+ T cells and then transduced with a lentiviral vector encoding an anti-CD19 CAR. This enables selective targeting and cytotoxicity against tumor cells expressing the B-cell-specific surface antigen CD19, which is overexpressed in various B-cell lineage malignancies. RJMty19 combines features of both adaptive and innate immunity, including high proportions of stem cell-like memory T cells (Tscm), resistance to host-versus-graft rejection, lack of graft-versus-host disease (GvHD), scalability for manufacturing, storability via cryopreservation, and rapid antitumor response through mechanisms such as perforin/granzyme-mediated cytotoxicity and cytokine release (e.g., IFN-γ, TNF-α). Clinical trials have shown promising safety profiles without dose-limiting toxicities or GvHD[1][3][4][5].

Other names

allogeneic anti-CD19 CAR double-negative T cells RJMty19CD19-CAR-DNT cellsCD-19-CAR-DNT cellsCD 19-CAR-DNT cells